si-544
/ selectION
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
July 03, 2025
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
(clinicaltrials.gov)
- P1 | N=45 | Completed | Sponsor: selectION Therapeutics GmbH | Active, not recruiting ➔ Completed
Trial completion • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
April 08, 2025
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: selectION Therapeutics GmbH | Recruiting ➔ Active, not recruiting
Enrollment closed • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
October 18, 2024
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: selectION Therapeutics GmbH | Trial completion date: Sep 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2024 ➔ Mar 2025
Trial completion date • Trial primary completion date • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
January 19, 2024
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: selectION Therapeutics GmbH | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
January 04, 2024
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: selectION Therapeutics GmbH
New P1 trial • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
November 13, 2023
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: selectION Therapeutics GmbH | Recruiting ➔ Completed | Phase classification: P1b ➔ P1
Phase classification • Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP
June 23, 2023
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P1b | N=36 | Recruiting | Sponsor: selectION Therapeutics GmbH | Trial completion date: Jun 2023 ➔ Nov 2023 | Trial primary completion date: Jun 2023 ➔ Nov 2023
Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP
May 30, 2023
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
(GlobeNewswire)
- P1b | N=36 | NCT05383378 | Sponsor: selectION Therapeutics GmbH | "selectION, Inc...announced excellent initial safety results of the single ascending dose (SAD) stage in the Phase 1b trial of its drug candidate si-544 in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3....In the first stage of the trial, no dose limiting toxicities (DLTs), or safety signals have been observed. Based on these encouraging results, the trial now progresses into the multiple ascending dose (MAD) stage, where patients will receive a one-month treatment cycle of si-544, followed by a monitoring period lasting three months."
P1 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
July 05, 2022
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P1b | N=36 | Recruiting | Sponsor: selectION Therapeutics GmbH | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP
May 20, 2022
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P1b | N=36 | Not yet recruiting | Sponsor: selectION Therapeutics GmbH
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP
1 to 10
Of
10
Go to page
1